Sansom Lloyd
School of Pharmacy and Medical Sciences, University of South Australia, Adelaide 5000, South Australia.
Aust Health Rev. 2004 Nov 8;28(2):194-205. doi: 10.1071/ah040194.
The increasing costs of health care, including new technologies and pharmaceuticals, pose challenges for all countries both in the developed and the developing world. It is essential that the increased expenditure on pharmaceuticals represents value for money and is seen as an investment in health care rather than simply the purchase of the latest released agent. The system in Australia uses a cost-effectiveness approach to guide the decisions as to whether a new drug can be recommended for subsidy. The need for a greater understanding and transparency of the processes is essential in order for a well-informed public debate to occur about the challenges to the system and its sustainability. The relevant issues are discussed in this article to assist that debate.
医疗保健成本不断上升，包括新技术和药品，这给发达国家和发展中国家都带来了挑战。药品支出的增加必须物有所值，应被视为对医疗保健的投资，而不仅仅是购买最新上市的药物。澳大利亚的系统采用成本效益方法来指导关于是否推荐新药进行补贴的决策。为了就该系统面临的挑战及其可持续性进行明智的公众辩论，必须更好地理解这些流程并提高透明度。本文将讨论相关问题以推动这一辩论。
